ES2329553T3 - Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. - Google Patents
Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. Download PDFInfo
- Publication number
- ES2329553T3 ES2329553T3 ES01994318T ES01994318T ES2329553T3 ES 2329553 T3 ES2329553 T3 ES 2329553T3 ES 01994318 T ES01994318 T ES 01994318T ES 01994318 T ES01994318 T ES 01994318T ES 2329553 T3 ES2329553 T3 ES 2329553T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- substituted
- case
- independently selected
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 18
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 4
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- -1 -OH Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract 2
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 abstract 1
- 125000006593 (C2-C3) alkynyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000004981 cycloalkylmethyl group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Un compuesto de la fórmula (I): **(Ver fórmula)** o un estereoisómero o una forma de sal farmacéuticamente aceptable del mismo, en el que: b es un enlace sencillo, donde los hidrógenos puente son cis o trans; X es -CH2-, R1 se selecciona entre H, alquilo C1-5, alquenilo C2-5, alquinilo C2-5, cicloalquilo C3-6, -(alquil C1-3) cicloalquilo C3-6, -(alquenil C2-3)cicloalquilo C3-6 y -(alquinil C2-3)cicloalquilo C3-6, R6a es H o alquilo C1-4; R6b es H; como alternativa, R6a y R6b se toman juntos para formar =O o =S; R7 y R9, en cada caso, se seleccionan independientemente entre H, halo, -CF3, -OCF3, -OH, -CN, -NO2, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, alcoxi C1-4 y (haloalquil C1-4)oxi; R8 se selecciona entre H; fenilo sustituido con O-S R33; y -NR12R13; R12, en cada caso, se selecciona independientemente entre alquilo C1-4 sustituido con 0-1 R12a, alquenilo C2-4 sustituido con 0-1 R12a, alquinilo C2-4 sustituido con 0-1 R12a, cicloalquilo C3-6 sustituido con 0-3 R33, arilo sustituido con 0-5 R33; resto carbocíclico C3-10 sustituido con 0-3 R33 y sistema de anillos heterocíclicos de 5-10 miembros que contiene 1-4 heteroátomos seleccionados entre el grupo constituido por N, O y S sustituido con 0-3 R31; R12a, en cada caso, se selecciona independientemente entre fenilo sustituido con 0-5 R33; resto carbocíclico C3-10 sustituido con 0-3 R33 y sistema de anillos heterocíclicos de 5-10 miembros que contiene de 1-4 heteroátomos seleccionados entre el grupo constituido por N, O y S sustituido con 0-3 R31; R13, en cada caso, se selecciona independientemente entre H, alquilo C1-4, alquenilo C2-4 y alquinilo C2-4; como alternativa, R12 y R13, cuando se unen a N, pueden combinarse para formar un anillo heterocíclico bicíclico de 9 ó 10 miembros que contiene 1-3 heteroátomos seleccionados entre el grupo constituido por N, O y S, donde dicho sistema de anillos heterocíclicos bicíclico está insaturado o parcialmente saturado, donde dicho sistema de anillos heterocíclicos bicíclico está sustituido con 0-3 R16; R16, en cada caso, se selecciona independientemente entre H, OH, halo, CN, NO2, CF3, SO2R45, NR46R47, -C(=O) H, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, haloalquilo C1-4, (haloalquil C1-3)-oxi-, (alquiloxi C1-3)-, y =O; R31, en cada caso, se selecciona independientemente entre H, OH, halo, CF3, SO2R45, NR46R47, alquilo C1-4 y =O; R33, en cada caso, se selecciona independientemente entre H, OH, halo, CN, NO2, CF3, SO2R 45, NR46R47, -C(=O)H, =O, fenilo, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, haloalquilo C1-4, (haloalquil C1-4)-oxi-, (alquiloxi C1-4)-, (alquiltio C1-4)-, (alquil C1-4)-C(=O)-, (alquil C1-4)-C(=O)NH-, (alquil C1-4)-OC(=O)-, (alquil C1-4)-C(=O)O-, (cicloalquil C3-6)-oxi-, (cicloalquilmetil C3-6)-oxi-; alquilo C1-6 sustituido con OH, metoxi, etoxi, propoxi, butoxi, -SO2R45, -NR46R47, NR46R47C(=O)- o (alquil C1-4)CO2-; y alquenilo C2-6 sustituido con OH, metoxi, etoxi, propoxi, butoxi, -SO2R45, -NR46R47, NR46R47C(=O)-, o (alquil C1-4)CO2-; R45 es alquilo C1-4; R46, en cada caso, se selecciona independientemente entre H y alquilo C1-4; R47, en cada caso, se selecciona independientemente entre H, alquilo C1-4, -C(=O)NH(alquilo C1-4), -SO2(alquilo C1-4), -C(=O)O(alquilo C1-4), -C(=O)( alquilo C1-4) y -C(=O)H; n es 1 ó 2; m es 1 ó 2; y n más m es 2, 3 ó 4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25674500P | 2000-12-20 | 2000-12-20 | |
| US256745P | 2000-12-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2329553T3 true ES2329553T3 (es) | 2009-11-27 |
| ES2329553T4 ES2329553T4 (es) | 2010-12-07 |
Family
ID=22973430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01994318T Expired - Lifetime ES2329553T4 (es) | 2000-12-20 | 2001-12-19 | Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6777406B2 (es) |
| EP (1) | EP1399445B9 (es) |
| JP (1) | JP4386639B2 (es) |
| KR (1) | KR20030070590A (es) |
| AT (1) | ATE438646T1 (es) |
| AU (1) | AU2002246726B2 (es) |
| BG (1) | BG107863A (es) |
| BR (1) | BR0116348A (es) |
| CA (1) | CA2432181C (es) |
| CZ (1) | CZ20031707A3 (es) |
| DE (1) | DE60139511D1 (es) |
| EE (1) | EE200300303A (es) |
| ES (1) | ES2329553T4 (es) |
| HU (1) | HUP0303530A3 (es) |
| IL (1) | IL156261A0 (es) |
| IS (1) | IS6851A (es) |
| MX (1) | MXPA03005355A (es) |
| NO (1) | NO20032798L (es) |
| PL (1) | PL366627A1 (es) |
| RU (1) | RU2003121306A (es) |
| SK (1) | SK7032003A3 (es) |
| WO (1) | WO2002059124A2 (es) |
| ZA (1) | ZA200304304B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR031200A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados |
| US6858604B2 (en) | 2000-11-03 | 2005-02-22 | Wyeth | Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives |
| AR031202A1 (es) | 2000-11-03 | 2003-09-10 | Wyeth Corp | Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados |
| TW200307540A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents |
| TWI312781B (en) | 2002-04-25 | 2009-08-01 | [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents | |
| TW200307682A (en) | 2002-04-25 | 2003-12-16 | Wyeth Corp | 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| EP2248524A3 (en) | 2004-08-25 | 2011-03-09 | Takeda Pharmaceutical Company Limited | Preventives/remedies for stress urinary incontinence and method of screening the same |
| US20070021612A1 (en) * | 2004-11-04 | 2007-01-25 | University Of Notre Dame Du Lac | Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof |
| US7235688B1 (en) | 2004-11-04 | 2007-06-26 | University Of Notre Dame Du Lac | Process for preparing histone deacetylase inhibitors and intermediates thereof |
| GT200500317A (es) * | 2004-11-05 | 2006-10-27 | Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos | |
| AR054849A1 (es) * | 2005-07-26 | 2007-07-18 | Wyeth Corp | Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas |
| TW200734334A (en) * | 2006-01-13 | 2007-09-16 | Wyeth Corp | Treatment of substance abuse |
| JP2009531434A (ja) * | 2006-03-24 | 2009-09-03 | ワイス | 痛みの治療 |
| CN101410112A (zh) * | 2006-03-24 | 2009-04-15 | 惠氏公司 | 治疗抑郁症的新治疗组合 |
| EP2742936A1 (en) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
| CL2008002777A1 (es) * | 2007-09-21 | 2010-01-22 | Wyeth Corp | Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario. |
| US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
| AU2010303270A1 (en) | 2009-10-09 | 2012-05-03 | Zafgen Corporation | Sulphone compounds for use in the treatment of obesity |
| EP2510949A4 (en) | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | THERAPEUTICS FOR FIBROMYALGIA |
| BR112013001613A2 (pt) * | 2010-07-22 | 2016-05-24 | Zafgen Inc | compostos tricíclicos e métodos para fazer e usar os mesmos. |
| US9321740B2 (en) | 2011-01-26 | 2016-04-26 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| BR112013028665A2 (pt) | 2011-05-06 | 2016-09-06 | Zafgen Inc | compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| MX343688B (es) | 2011-05-06 | 2016-11-16 | Zafgen Inc | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. |
| KR101979039B1 (ko) | 2011-05-06 | 2019-05-15 | 자프겐 인크. | 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법 |
| US9440943B2 (en) | 2012-01-18 | 2016-09-13 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| JP6035347B2 (ja) | 2012-01-18 | 2016-11-30 | ザフゲン，インコーポレイテッド | 三環式スルホンアミド化合物ならびにその作製および使用方法 |
| KR20150080614A (ko) | 2012-11-05 | 2015-07-09 | 자프겐 인크. | 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물 |
| NZ707773A (en) | 2012-11-05 | 2019-05-31 | Zafgen Inc | Methods of treating liver diseases |
| MX2015005732A (es) | 2012-11-05 | 2015-12-16 | Zafgen Inc | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. |
| EP2919788A4 (en) | 2012-11-14 | 2016-05-25 | Univ Johns Hopkins | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA |
| EP2981266B1 (en) * | 2013-03-04 | 2018-01-03 | Daya CNS LLC | Pentacyclic pyridoindolobenz[b,d]azepine derivatives and uses thereof |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE |
| CN109897039B (zh) * | 2019-03-13 | 2021-03-30 | 中国科学院化学研究所 | 一种制备吡咯并[3,2,1-ij]喹啉酮化合物的方法 |
| US20240208973A1 (en) * | 2021-04-13 | 2024-06-27 | The Regents Of The University Of California | Tetracyclic compounds for treating brain disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4013652A (en) | 1972-06-19 | 1977-03-22 | Endo Laboratories, Inc. | Pyridopyrrolobenzoxazine |
| US4238607A (en) | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US3914421A (en) | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4115577A (en) | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4183936A (en) | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4219550A (en) | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| HUT61548A (en) * | 1990-08-27 | 1993-01-28 | Sandoz Ag | Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds |
-
2001
- 2001-12-19 IL IL15626101A patent/IL156261A0/xx unknown
- 2001-12-19 KR KR10-2003-7008267A patent/KR20030070590A/ko not_active Application Discontinuation
- 2001-12-19 AU AU2002246726A patent/AU2002246726B2/en not_active Ceased
- 2001-12-19 ES ES01994318T patent/ES2329553T4/es not_active Expired - Lifetime
- 2001-12-19 AT AT01994318T patent/ATE438646T1/de not_active IP Right Cessation
- 2001-12-19 EE EEP200300303A patent/EE200300303A/xx unknown
- 2001-12-19 HU HU0303530A patent/HUP0303530A3/hu unknown
- 2001-12-19 RU RU2003121306/04A patent/RU2003121306A/ru not_active Application Discontinuation
- 2001-12-19 MX MXPA03005355A patent/MXPA03005355A/es unknown
- 2001-12-19 CA CA002432181A patent/CA2432181C/en not_active Expired - Fee Related
- 2001-12-19 PL PL01366627A patent/PL366627A1/xx unknown
- 2001-12-19 DE DE60139511T patent/DE60139511D1/de not_active Expired - Lifetime
- 2001-12-19 CZ CZ20031707A patent/CZ20031707A3/cs unknown
- 2001-12-19 WO PCT/US2001/049380 patent/WO2002059124A2/en active IP Right Grant
- 2001-12-19 SK SK703-2003A patent/SK7032003A3/sk unknown
- 2001-12-19 US US10/026,993 patent/US6777406B2/en not_active Expired - Lifetime
- 2001-12-19 BR BR0116348-5A patent/BR0116348A/pt not_active Application Discontinuation
- 2001-12-19 EP EP01994318A patent/EP1399445B9/en not_active Expired - Lifetime
- 2001-12-19 JP JP2002559426A patent/JP4386639B2/ja not_active Expired - Fee Related
-
2003
- 2003-05-30 BG BG107863A patent/BG107863A/xx unknown
- 2003-06-02 ZA ZA200304304A patent/ZA200304304B/en unknown
- 2003-06-18 IS IS6851A patent/IS6851A/is unknown
- 2003-06-19 NO NO20032798A patent/NO20032798L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20040092502A1 (en) | 2004-05-13 |
| KR20030070590A (ko) | 2003-08-30 |
| CA2432181C (en) | 2009-11-17 |
| JP4386639B2 (ja) | 2009-12-16 |
| EP1399445B1 (en) | 2009-08-05 |
| HUP0303530A3 (en) | 2012-10-29 |
| NO20032798D0 (no) | 2003-06-19 |
| MXPA03005355A (es) | 2004-05-27 |
| IL156261A0 (en) | 2004-01-04 |
| ES2329553T4 (es) | 2010-12-07 |
| CA2432181A1 (en) | 2002-08-01 |
| NO20032798L (no) | 2003-08-19 |
| DE60139511D1 (de) | 2009-09-17 |
| RU2003121306A (ru) | 2005-03-10 |
| ZA200304304B (en) | 2004-09-02 |
| HUP0303530A2 (hu) | 2004-01-28 |
| EE200300303A (et) | 2003-12-15 |
| PL366627A1 (en) | 2005-02-07 |
| WO2002059124A3 (en) | 2004-01-08 |
| CZ20031707A3 (cs) | 2003-11-12 |
| EP1399445A2 (en) | 2004-03-24 |
| BG107863A (en) | 2004-06-30 |
| EP1399445B9 (en) | 2010-07-21 |
| IS6851A (is) | 2003-06-18 |
| SK7032003A3 (en) | 2004-04-06 |
| BR0116348A (pt) | 2004-11-23 |
| JP2004528290A (ja) | 2004-09-16 |
| AU2002246726B2 (en) | 2007-03-01 |
| ATE438646T1 (de) | 2009-08-15 |
| US6777406B2 (en) | 2004-08-17 |
| WO2002059124A2 (en) | 2002-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2329553T3 (es) | Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. | |
| AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
| AR013493A1 (es) | COMPUESTO DE QUINOLONA, SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO Y COMPOSICIoN FARMACEUTICA QUE LO COMPRENDE | |
| AR046394A1 (es) | Derivados de quinolinas y quinazolinas, metodo de preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
| AR049883A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR049443A1 (es) | Derivados de pirrolpiridinas | |
| PE20030890A1 (es) | Cumarinas utiles como biomarcadores | |
| CO4990929A1 (es) | Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8 | |
| AR040074A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamentos, e intermediarios para la preparacion de dichos compuestos | |
| AR059571A1 (es) | Derivados de octahidro-pirrolo[3,4-c]pirrol, composiciones farmaceuticas | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| PE20060932A1 (es) | Derivados de sulfonamidas como moduladores de receptores de glucocorticoides (gr) | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| CO5700725A2 (es) | Derivados sustituidos de la ciclohexano-1,4-diamina | |
| AR063601A1 (es) | Arilamidas sustituidas por tiazol u oxazol | |
| CO6160229A2 (es) | Ciclopenta [d] pirimidinas como inhibidores de proteina quinasa akt | |
| CR7950A (es) | Sintesis de los cloruros de 4amino -2butenoilo y su uso en la preparacion of 3- cianoquinolinas | |
| AR085544A1 (es) | Inhibidores triciclicos fusionados dobles de las cdk 4/6 y de la flt3 | |
| AR040095A1 (es) | Agentes moduladores del receptor de calcio | |
| CO5690582A2 (es) | Derivados de n-tiazol-2-il-benzamida | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR044342A1 (es) | Derivados de bencimidazol | |
| AR037681A1 (es) | Antagonistas receptores de adenosina a2a de 5-amino-[1,2,4]-triazol biciclico, composiciones farmaceuticas que los comprenden, el uso de las mismas, solo o en combinacion de los compuestos y otros agentes para la preparacion de medicamentos utiles en el tratamiento de la enfermedad de parkinson y un | |
| AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos |